TheraRadar
Data updated: May 30, 2026

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol)

Women's Health Approved 2003-04-29

Levonorgestrel and ethinyl estradiol tablets, 0.15 mg/30 mcg are indicated for use by females of reproductive potential to prevent pregnancy.

Source: FDA Label • WATSON LABS
20
Indications
--
Phase 3 Trials
23
Years on Market

Details

Status
Prescription
First Approved
2003-04-29
Routes
ORAL, ORAL-28, ORAL-21
Dosage Forms
TABLET

LEVONORGESTREL AND ETHINYL ESTRADIOL Approval History

2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
70 FDA actions from 2003 to 2025
May 2025 SUPPL
Label · Labeling
Dec 2024 SUPPL
Label · Labeling
Jan 2024 SUPPL
Label · Labeling

What LEVONORGESTREL AND ETHINYL ESTRADIOL Treats

20 FDA approvals

Originally approved for its first indication in 2003 . Covers 20 distinct patient populations.

  • Other (20)

LEVONORGESTREL AND ETHINYL ESTRADIOL Boxed Warning

CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including levonorgestrel and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke [see CONTRAINDICATIONS and WARNINGS (1) ]....

📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT07340190 CDAK539A12102 2025-521000-22-00 Ph 1 not yet recruiting A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
NCT06039826 18533 J1I-MC-GZBV Ph 1 completed A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
NCT02531321 results posted HS-15-00112 Ph 4 terminated Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVONORGESTREL AND ETHINYL ESTRADIOL FDA Label Details

Indications & Usage

FDA Label (PDF)

Levonorgestrel and ethinyl estradiol tablets, 0.15 mg/30 mcg are indicated for use by females of reproductive potential to prevent pregnancy.

⚠️ BOXED WARNING

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For th...

Track LEVONORGESTREL AND ETHINYL ESTRADIOL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.